191 related articles for article (PubMed ID: 19217980)
1. Gefitinib plus docetaxel in non-small-cell lung cancer.
Singh N; Aggarwal AN
Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
[No Abstract] [Full Text] [Related]
2. Gefitinib plus docetaxel in non-small-cell lung cancer.
Zalcman G; Bergot E
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
[No Abstract] [Full Text] [Related]
3. Gefitinib plus docetaxel in non-small-cell lung cancer.
Costa DB; Kobayashi S
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
[No Abstract] [Full Text] [Related]
4. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
Zhao YL; Han S; Pu R; Shi LW
Indian J Cancer; 2014 Mar; 51 Suppl 3():e86-91. PubMed ID: 25818741
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Sun Y; Wu YL; Li LY; Liao ML; Jiang GL; Kim ES; Douillard JY; Milenkova T
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):377-80. PubMed ID: 21875470
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Cullen M; Thatcher N
Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
[No Abstract] [Full Text] [Related]
10. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R; Nishiwaki Y; Tamura T; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Inoue A; Tomii K; Harada M; Masuda N; Jiang H; Itoh Y; Ichinose Y; Saijo N; Fukuoka M
J Clin Oncol; 2008 Sep; 26(26):4244-52. PubMed ID: 18779611
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Johnson DH; Arteaga CL
J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
[No Abstract] [Full Text] [Related]
12. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Horgan AM; Bradbury PA; Amir E; Ng R; Douillard JY; Kim ES; Shepherd FA; Leighl NB
Ann Oncol; 2011 Aug; 22(8):1805-11. PubMed ID: 21273345
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
15. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
16. Gefitinib versus docetaxel for previously treated NSCLC--letter.
Tassinari D; Lazzari-Agli L; Tombesi P; Sartori S
Clin Cancer Res; 2011 Jul; 17(13):4610; author reply 4611. PubMed ID: 21712456
[No Abstract] [Full Text] [Related]
17. One more fallen star--ZODIAC and its implications.
Stinchcombe TE; Govindan R
Lancet Oncol; 2010 Jul; 11(7):604-5. PubMed ID: 20610317
[No Abstract] [Full Text] [Related]
18. The TAILOR study: to agree or to disagree?
Moro-Sibilot D; Perol D; Chabaud S; Cadranel J; Audigier Valette C; Perol M
Lung Cancer; 2014 Jun; 84(3):315-6. PubMed ID: 24751106
[No Abstract] [Full Text] [Related]
19. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
20. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
